Skip to Content
Merck

LO4100

LOPAC®1280 - Small Scale

Synonym(s):

Library of Pharmacologically Active Compounds - small scale

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
12352200
EC Number:
200-664-3
NACRES:
NA.77
Form:
liquid
Quality level:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


form

liquid

Quality Level

drug control

Új pszichoaktív anyag / New psychoactive substance (Hungary), 78/2022. (XII. 28.) BM rendelet

shipped in

dry ice

storage temp.

−20°C

General description

Compounds are arranged in 96-well format in 16 racks of 80, one compound per well (25 μl at 10 mM in DMSO in archival storage racks).
LOPAC® 1280 is an extensively used library of pharmacologically active compounds. This library includes 1,280 marketed drugs, failed development candidates, and small molecules with well-characterized activities. LOPAC 1280 spans a broad molecular weight range, exhibits multiple mechanisms of action and interacts with a variety of biological receptors.

Application

LOPAC® 1280 - Small Scale has been used:
  • in sprouting assay to screen potential lymphangiogenic inhibitors and the signaling pathways involved in lymphangiogenesis
  • for identification of neuroactive compounds by measuring spontaneous activity within single zebrafish embryos by high-content screening assay
  • for high-throughput Screen for ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1; also known as CD39) and ecto-5′-nucleotidase (CD73) inhibitors

Features and Benefits

Includes the latest, drug-like molecules in the fields of Cell Signaling & Neuroscience:

  • Apoptosis
  • G Proteins & Cyclic Nucleotides
  • Gene Regulation & Expression
  • Ion Channels
  • Lipid Signaling
  • Multi-Drug Resistance
  • Neurotransmission
  • Phosphorylation
SDFile provided to construct a database containing:
  • Structure
  • Primary Name
  • Secondary Name
  • Pharmacological Activity
  • Product Number
  • Rack Position

Other Notes

For sale inside of the U.S. only. Customers outside the US should refer to Product Code LO4200.

Legal Information

LOPAC is a registered trademark of Merck KGaA, Darmstadt, Germany


Still not finding the right product?

Explore all of our products under LOPAC®1280 - Small Scale


signalword

Danger

Hazard Classifications

Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Eye Dam. 1 - Lact. - Muta. 1B - Repr. 1A - Resp. Sens. 1 - Skin Corr. 1B - Skin Sens. 1 - STOT RE 2 - STOT SE 2

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

flash_point_f

188.6 °F

flash_point_c

87 °C

wgk

WGK 3



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Sara M Vliet et al.
Toxicology and applied pharmacology, 329, 241-248 (2017-06-18)
Spontaneous activity represents an early, primitive form of motor activity within zebrafish embryos, providing a potential readout for identification of neuroactive compounds. However, despite use as an endpoint in chemical screens around the world, the predictive power and limitations of
Miao Xu et al.
Nature medicine, 22(10), 1101-1107 (2016-08-30)
In response to the current global health emergency posed by the Zika virus (ZIKV) outbreak and its link to microcephaly and other neurological conditions, we performed a drug repurposing screen of ∼6,000 compounds that included approved drugs, clinical trial drug
Meera Kumar et al.
SLAS discovery : advancing life sciences R & D, 25(3), 320-326 (2019-12-24)
Production of adenosine in the extracellular tumor microenvironment elicits strong immunosuppression and is associated with tumor progression. Thus, targeting adenosine-generating ectonucleotidases is a potential strategy to stimulate and prolong antitumor immunity. Because the reaction products of ectonucleotidases differ by a